Literature DB >> 3479534

The mechanism and overcoming of resistance in ACNU-resistant sublines of C6 and 9L rat glioma.

T Yoshida1, K Shimizu, Y Ushio, T Hayakawa, H Mogami, Y Sakamoto.   

Abstract

In order to study the mechanism of the resistance to chemotherapeutic agents, especially ACNU [1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride), two variant cell lines (C6/ACNU and 9L/ACNU) resistant to ACNU were selected in vivo from rat C6 and 9L glioma, respectively. Uptake and efflux of ACNU in these resistant cells were studied with Ethylene[14C]ACNU. The result indicated that the resistance exhibited by both sublines were due to both the reduced uptake of the drug and the increased efflux. The study of the effects of oxidative phosphorylation inhibitor, DNP (2,4-dinitrophenol), on the uptake and retention of ACNU suggested that there is an active outward transport mechanism for ACNU in both glioma sublines and that enhanced activity of this efflux mechanism renders cells highly resistant to the cytotoxic action of ACNU. In an attempt to clarify the more detailed biochemical mechanisms of this active efflux system, we surveyed various membrane-modifying agents which potentiate the sensitivity of these resistant cells to ACNU. Among a number of membrane-modifying agents, reserpine was found to retain ACNU in the resistant cells and to enhance the action of ACNU on these resistant cell lines. It may be concluded that drugs such as reserpine may overcome a mechanism of ACNU resistance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3479534     DOI: 10.1007/BF00151222

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  Calcium-reserpine interactions studied by electron spin resonance spectroscopy in spin labeled artificial membranes.

Authors:  U K Wang; S Radouco-Thomas
Journal:  Prog Neuropsychopharmacol       Date:  1978

2.  Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumor in vivo.

Authors:  K Danø
Journal:  Cancer Chemother Rep       Date:  1972-06

3.  Collateral sensitivity to methotrexate in cells resistant to adriamycin.

Authors:  T S Herman; A E Cress; E W Gerner
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

4.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

Authors:  K Dano
Journal:  Biochim Biophys Acta       Date:  1973-10-25

5.  Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).

Authors:  R K Johnson; A A Ovejera; A Goldin
Journal:  Cancer Treat Rep       Date:  1976-01

6.  Drug sensitivity of an adriamycin-resistant mutant subline of mouse lymphoblastoma L5178Y cells.

Authors:  T Nishimura; K Muto; N Tanaka
Journal:  J Antibiot (Tokyo)       Date:  1978-05       Impact factor: 2.649

7.  Investigation of resistance to DNA cross-linking agents in 9L cell lines with different sensitivities to chloroethylnitrosoureas.

Authors:  W J Bodell; M Gerosa; T Aida; M S Berger; M L Rosenblum
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

8.  Modulation in vitro and in vivo of ACNU resistance in a subline of C6 glioma with reserpine.

Authors:  T Yoshida; K Shimizu; Y Ushio; H Mogami; Y Sakamoto
Journal:  J Neurosurg       Date:  1987-02       Impact factor: 5.115

9.  Detection of induced resistance in short-term-tests. Adriamycin-resistant sarcoma 180.

Authors:  M Volm; C Lindner
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-01-26

10.  [Development of ACNU-resistant meningeal gliomatosis models: establishment of resistant rat glioma subline against ACNU].

Authors:  T Yoshida; Y Ushio; T Hayakawa; K Yamada; A Kato; H Mogami; Y Nakata
Journal:  No Shinkei Geka       Date:  1984-08
View more
  2 in total

Review 1.  Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas.

Authors:  R F Barth
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

Review 2.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.